ZAI LAB LTD0000006 (1ZLB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ZAI LAB LTD0000006 (1ZLB) has a cash flow conversion efficiency ratio of -0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.91 Million ≈ $-13.93 Million USD) by net assets (€661.98 Million ≈ $773.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 1ZLB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
ZAI LAB LTD0000006 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ZAI LAB LTD0000006's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ZAI LAB LTD0000006 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZAI LAB LTD0000006 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wisdom Marine Lines Co Ltd
TW:2637
|
0.055x |
|
Systemair AB
ST:SYSR
|
0.073x |
|
Ningbo Kangqiang Electronics Co Ltd
SHE:002119
|
0.001x |
|
Monadelphous Group Ltd
F:8MP
|
0.043x |
|
Wasu Media Holding Co Ltd
SHE:000156
|
0.026x |
|
Pharvaris BV
NASDAQ:PHVS
|
-0.098x |
|
Nancal Energy-Saving Tech Co
SHG:603859
|
-0.014x |
|
Jiugui Liquor Co Ltd
SHE:000799
|
-0.028x |
Annual Cash Flow Conversion Efficiency for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ZAI LAB LTD0000006 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see ZAI LAB LTD0000006 (1ZLB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €715.50 Million ≈ $836.49 Million |
€-150.79 Million ≈ $-176.29 Million |
-0.211x | +17.52% |
| 2024-12-31 | €840.90 Million ≈ $983.10 Million |
€-214.87 Million ≈ $-251.20 Million |
-0.256x | -2.65% |
| 2023-12-31 | €796.12 Million ≈ $930.75 Million |
€-198.18 Million ≈ $-231.69 Million |
-0.249x | +29.20% |
| 2022-12-31 | €1.05 Billion ≈ $1.22 Billion |
€-367.64 Million ≈ $-429.81 Million |
-0.352x | +11.66% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€-549.23 Million ≈ $-642.11 Million |
-0.398x | -- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more